Information Provided By:
Fly News Breaks for April 25, 2018
RIGL
Apr 25, 2018 | 09:20 EDT
Piper Jaffray analyst Christopher Raymond believes last week's follow-on offering removes an overhang on shares of Rigel Pharmaceuticals. The capital raise clears the way for what will be a "meaningful update" when Rigel reports earnings on May 1, and provides more detail on the upcoming Tavalisse launch plans, Raymond tells investors in a research note. He remains a buyer of the stock with an Overweight rating and $7 price target.
News For RIGL From the Last 2 Days
There are no results for your query RIGL